22 February 2024
Underlying operating profit of £1.6bn and underlying margin of 10.3%, reflecting the impact of our strategic initiatives, with commercial optimisation and cost efficiency benefits…
22 February 2024 LLOYDS BANKING GROUP PLC – ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2023 In accordance with Listing Rule…
21 February 2024
Nestlé reports full-year results for 2023 FEB 22, 2024 Back to Press releases Vevey, Switzerland [Ad hoc announcement pursuant to Art. 53 LR] Follow…
21 February 2024 07:00 GMT Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission AstraZeneca PLC (the Company) announced today that,…
21 February 2024 Production growth of 3% from focused investment in the health of our business; underlying EBITDA of $23.9 billion and full year ordinary…
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals…
19 February 2024
19 February 2024 Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial First EGFR inhibitor…
19 February 2024 B.P. Marsh & Partners Plc (“B.P. Marsh”, the “Company” or the “Group”) Trading Update The Directors of B.P. Marsh & Partners…